R1 RCM (NASDAQ:RCM – Get Rating) had its price objective lowered by JPMorgan Chase & Co. from $33.00 to $11.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the healthcare provider’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 42.67% from the stock’s current price.
Other equities analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft cut their price target on shares of R1 RCM from $31.00 to $14.00 in a report on Thursday, November 10th. SVB Leerink cut their price target on shares of R1 RCM from $35.00 to $16.00 and set an “outperform” rating for the company in a report on Wednesday, November 9th. Royal Bank of Canada cut their price target on shares of R1 RCM from $35.00 to $12.00 and set an “outperform” rating for the company in a report on Wednesday, November 9th. KeyCorp cut their price target on shares of R1 RCM from $30.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, November 9th. Finally, Truist Financial initiated coverage on shares of R1 RCM in a report on Wednesday, September 7th. They issued a “buy” rating and a $29.00 price target for the company. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.
R1 RCM Stock Up 2.3 %
RCM stock opened at $7.71 on Friday. The company has a fifty day moving average of $16.40 and a 200-day moving average of $20.36. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.54 and a current ratio of 1.56. The stock has a market capitalization of $3.21 billion, a PE ratio of 128.50 and a beta of 0.94. R1 RCM has a one year low of $6.71 and a one year high of $27.86.
Insider Transactions at R1 RCM
Institutional Investors Weigh In On R1 RCM
Hedge funds and other institutional investors have recently modified their holdings of the company. Twin Tree Management LP acquired a new stake in shares of R1 RCM in the first quarter worth approximately $28,000. Captrust Financial Advisors boosted its position in shares of R1 RCM by 81.7% in the second quarter. Captrust Financial Advisors now owns 1,664 shares of the healthcare provider’s stock worth $35,000 after acquiring an additional 748 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of R1 RCM in the second quarter worth approximately $49,000. Macquarie Group Ltd. boosted its position in shares of R1 RCM by 11.0% in the second quarter. Macquarie Group Ltd. now owns 4,159 shares of the healthcare provider’s stock worth $88,000 after acquiring an additional 411 shares during the last quarter. Finally, Point72 Hong Kong Ltd boosted its position in shares of R1 RCM by 100.5% in the first quarter. Point72 Hong Kong Ltd now owns 4,203 shares of the healthcare provider’s stock worth $112,000 after acquiring an additional 2,107 shares during the last quarter. 49.86% of the stock is currently owned by hedge funds and other institutional investors.
About R1 RCM
R1 RCM Inc provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers.
- Get a free copy of the StockNews.com research report on R1 RCM (RCM)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.